This discovery provides a new layer of understanding of TME-tumor cell crosstalk and presents MFAP4 as a promising biomarker and therapeutic target.A key strength of our prognostic signature lies in its ability to reflect the underlying immune landscape of TNBC. Here, MFAP4 is linked to neoplasm.